Evidence map›Paper›PMID 39203951›Full record

ArticleVaccines2024

An Interrupted Time Series Analysis of the Impact of the COVID-19 Pandemic on Routine Vaccination Uptake in Kenya.

Michael Ngigi, Yola Moride, Anne-Marie Castilloux, Sue Ann Costa Clemens

Abstract read
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Assessing the impact of the COVID-19 pandemic on routine childhood vaccination uptake, the Netherlands, 2016 to 2025.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026
    Article
  2. Article
  3. Rethinking the evidence on COVID-19 in Africa.The Lancet. Infectious diseases · 2025
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Michael NgigiInstitute for Global Health, Centro Servizi di Ateneo Santa Chiara Lab, University of Siena, 53100 Siena, Italy.ORCID 0000-0002-0256-4163
Yola MorideCenter for Pharmacoepidemiology and Treatment Science, Rutgers, The State University of New Jersey, New Brunswick, NJ 08854, USA.
Anne-Marie CastillouxYola RX Consultants, Montreal, QC H3H 1V4, Canada.
Sue Ann Costa ClemensInstitute for Global Health, Centro Servizi di Ateneo Santa Chiara Lab, University of Siena, 53100 Siena, Italy.ORCID 0000-0001-9576-0878

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A strategic priority of the World Health Organization's Immunization Agenda 2030 is to increase vaccination coverage and equity through reaching "zero-dose" children. Through an ecological study, we sought to quantify the impact of the COVID-19 pandemic on the coverage of the pentavalent and the measles/rubella vaccines in Kenya, without implying causality. The monthly number of doses from January 2017 to August 2022 were obtained from the Kenya Health Information System for the pentavalent and the measles/rubella vaccines. Immediate (step) and long-term (ramp) changes following interruptions occurring during the period from March 2020 to December 2020 were assessed through an interrupted time series analysis using an autoregressive integrated moving average (ARIMA) model, accounting for seasonality. In December 2020, there was an immediate decrease of 8337, 12,212, and 20,848 in the number of doses for the first, second, and third dose of the pentavalent vaccine, respectively (statistically significant for the third dose only). This corresponded to a percentage relative difference of -21.6, -20.1, and -24.5, respectively, for three doses of pentavalent vaccines, while for measles/rubella vaccine it was -27.3 and -33.6, respectively, for the first and second dose. COVID-19 resulted in interruptions affecting routine immunization, but recovery occurred within four months.

Indexed as

ARIMACOVID-19epidemiologyimmunizationinterrupted time seriesmodellingpublic healthroutine immunizationvaccination

Identifiers

PMID39203951
PMCPMC11359163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.